Moneycontrol
HomeNewsBusinessHexaware's delisting will not affect its operations, employees or clients: CEO R Srikrishna
Trending Topics

Hexaware's delisting will not affect its operations, employees or clients: CEO R Srikrishna

The result of the shareholder voting to consider the proposed delisting will be out on August 10, after which the timeline for the same, if it happens, would emerge.

October 10, 2020 / 11:03 IST
Story continues below Advertisement

Delisting of mid-tier IT firm Hexaware Technologies by promoter Baring Asia PE will have no impact on its operations or employees and clients, R Srikrishna, CEO, Hexaware, told Moneycontrol on July 28.

In an interaction with Moneycontrol, Srikrishna said that clients have so far raised no concerns over the move, and there are no issues on retaining employees either. “The whole idea is to continue as it is,” he added.

Story continues below Advertisement

In an earnings call on July 28, he said that if the delisting goes through, employees with company stocks would be adequately compensated. This could be through ownership plans similar to restricted stock units (RSU), he said. RSU is a compensation issued to employees in the form of company shares.

The results of the shareholder voting to consider delisting will be out on August 10, post which the timeline for the same, if it happens, would emerge, he said.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show